Physician profile
Sunit Tolia
NPI 1427493865
$2,516.89
in general payments reported to CMS, 2019-2025
25 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $989 · 2020: $239 · 2021: $319 · 2022: $436 · 2023: $152 · 2024: $264 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $533.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $347.34 | 2019-2025 | Repatha, Repatha |
| United Therapeutics Corporation | $333.84 | 2021-2022 | |
| Abbott Laboratories | $299.31 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $276.33 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $182.87 | 2019-2024 | Opsumit, Uptravi |
| Janssen Pharmaceuticals, INC | $174.71 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.71 | 2019-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $114.35 | 2019-2025 | Camzyos, Eliquis |
| Medtronic Vascular, INC. | $111.25 | 2019 | |
| Novo Nordisk INC | $56.46 | 2023-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $49.73 | 2019-2024 | Wainua |
| Pfizer INC. | $49.16 | 2019-2025 | |
| Esperion Therapeutics, INC. | $47.04 | 2024 | Nexletol |
| Sanofi-Aventis U.S. LLC | $46.43 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $45.63 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $38.46 | 2022 | |
| Scpharmaceuticals INC. | $34.98 | 2023-2024 | |
| Boston Scientific Corporation | $30.78 | 2024 | Watchman Flx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.89 | 2019-2024 | Lifevest |
| Portola Pharmaceuticals, LLC | $21.57 | 2019 | |
| Cvrx, INC. | $17.48 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.46 | 2019 | |
| Merck Sharp & Dohme LLC | $15.56 | 2025 | Verquvo |
| Alnylam Pharmaceuticals INC. | $15.07 | 2024 | Onpattro |
| Irhythm Technologies, INC. | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunit Tolia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.